What is the current market size?

The postoperative pain control drug market size was valued at USD 1.2 billion in 2023, driven by rising surgical volumes and demand for effective analgesics.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, fueled by advancements in pain management therapies and an aging global population.

What are the key drivers of market growth?

Key drivers include increasing postoperative pain management needs, a surge in orthopedic and cardiac surgeries, and the adoption of non-opioid analgesic alternatives.

What challenges does the market face?

Challenges include stringent regulatory approvals, opioid dependence risks, and the high cost of innovative pain control therapies.

Which regions are leading the market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and high surgical procedure rates.

Who are the top companies in the market?

Leading companies include Pfizer, Johnson & Johnson, and Baxter, which focus on R&D for non-opioid analgesics and strategic partnerships.

What future opportunities exist?

Opportunities lie in personalized pain management solutions, biologics, and expanding applications in ambulatory surgical centers.

How is technology impacting the market?

AI-driven drug discovery and wearable pain monitoring devices are enhancing precision in postoperative pain control, improving patient outcomes.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA prioritize safer analgesic options, influencing market approval pathways and post-market monitoring requirements.

postoperative pain control drug Market 2026: Primary Research + Expert Analysis

postoperative pain control drug by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), by Types (Opioids, NSAIDs, Local Anesthetics, Tricyclic Antidepressants, Antiepileptic Drugs, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12800 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $12800 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

postoperative pain control drug Market Overview

The postoperative pain control drug market encompasses pharmaceutical products designed to manage acute pain following surgical procedures, addressing a critical unmet need in global healthcare. With the postoperative pain control drug market size estimated at USD 13.2 billion in 2025, the sector is poised for robust growth outlook through 2033, driven by rising surgical volumes and aging populations. This industry expansion is underpinned by advancements in analgesic therapies and evolving regulatory frameworks prioritizing safer pain management solutions.

Loading chart…

The market is projected to grow at a CAGR of 6.1% from 2026 to 2033, fueled by macro drivers such as the proliferation of minimally invasive surgeries and the opioid crisis spurring demand for non-addictive alternatives. Key forces shaping the industry include: 1) Technological shifts toward multimodal analgesia combining regional anesthesia and targeted delivery systems, and 2) Regulatory tailwinds promoting reduced opioid use in favor of safer, non-opioid analgesics. North America remains the largest market due to high surgical adoption rates, while Asia-Pacific is the fastest-growing region, driven by expanding healthcare access and urbanization.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 billion
Revenue forecast in 2033	22.32 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mallinckrodt Pharmaceuticals; Pfizer; Novartis; Eli Lilly and Company; Teva Pharmaceutical Industries; Camurus; Bayer; Pacira BioSciences; Trevena
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising surgical procedure volumes globally are accelerating demand in the postoperative pain control drug market. Aging populations and rising prevalence of chronic diseases are driving surgical interventions, particularly in developed markets, while emerging economies are expanding access to elective procedures.

Advancements in targeted drug delivery systems and non-opioid analgesics are positioning innovative formulations as key growth drivers. These technologies reduce adverse effects and align with regulatory priorities, enhancing adoption in hospitals and ambulatory care settings.

Restraints2 items

Stringent opioid regulations in the U.S. and EU are limiting market expansion for traditional pain management therapies. Regulatory bodies are prioritizing abuse-deterrent formulations and non-opioid alternatives, creating market fragmentation.

Cost containment pressures from payers and governments are reducing pricing flexibility. Biosimilar competition and value-based purchasing models are further compressing margins for branded players in the postoperative pain control drug market size.

Opportunities2 items

Expansion into emerging markets in Asia-Pacific and Latin America presents high-growth potential. Rising healthcare expenditure and urbanization are fueling demand for advanced pain therapies, albeit with distribution and reimbursement infrastructure challenges.

Digital health integration offers opportunities for remote patient monitoring and personalized pain management solutions. Digital therapeutics and AI-driven dosing optimization could differentiate offerings in a competitive landscape.

Challenges2 items

Supply chain vulnerabilities in active pharmaceutical ingredient (API) sourcing, particularly from politically unstable regions, threaten product availability. Diversification of manufacturing hubs is critical to mitigate risks.

Clinical uncertainty around long-term safety of novel non-opioid analgesics is delaying adoption. Real-world evidence generation and comparative effectiveness studies are essential to build provider confidence and secure reimbursement.

Market Segmentation

Loading chart…

Application is a critical axis of postoperative pain control drug segmentation, reflecting the clinical contexts where these drugs are utilized. General surgery accounts for the largest share, driven by high procedural volumes and standardization of multimodal analgesia protocols. Orthopedic surgeries follow, with demand fueled by aging populations and rising joint replacement procedures. Neurosurgery and cardiac surgery represent niche but high-growth segments due to their reliance on potent analgesics to manage severe postoperative pain. Regional anesthesia techniques in these fields further diversify application dynamics. Each application contributes to the overall market size through differential drug utilization rates, with general surgery dominating due to its broad procedural base and frequent use of opioids and NSAIDs.

Types segmentation categorizes the postoperative pain control drug market by therapeutic class. Opioids, including morphine and fentanyl, remain dominant for severe pain but face declining growth due to regulatory scrutiny and opioid crisis awareness. NSAIDs (e.g., ibuprofen, COX-2 inhibitors) capture a significant share in moderate pain management, benefiting from their anti-inflammatory properties and reduced addiction risks. Local anesthetics (e.g., bupivacaine) are gaining traction through nerve block techniques, particularly in orthopedic and breast surgeries. Others encompass adjuvant therapies like gabapentinoids and ketamine, which address neuropathic pain and opioid-sparing effects. This typology influences market taxonomy through evolving clinical guidelines, payer coverage policies, and the push toward non-opioid alternatives in postoperative care.

postoperative pain control drug Segmentation Breakdown12 items

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Types

Opioids

NSAIDs

Local Anesthetics

Tricyclic Antidepressants

Antiepileptic Drugs

Others

Regional Insights

Loading chart…

The postoperative pain control drug market growth is led by North America, which dominates with ~40% global share, driven by advanced healthcare infrastructure, high adoption of innovative therapies, and robust R&D investments. Asia Pacific is the fastest-growing region, expanding at a CAGR exceeding 9% through 2030, fueled by rising surgical volumes, urbanization, and improving access to anesthesia services. Regulatory frameworks prioritizing patient outcomes in Europe (~30% share) and a strong ecosystem of pharmaceutical players further solidify its mature market position.

Regional Drivers & Dynamics5 items

North America: Aging demographics, high prevalence of chronic conditions, and payer reimbursement policies favoring advanced analgesics.

Europe: Stringent postoperative pain management guidelines, strong geriatric care infrastructure, and cross-border collaborations for drug innovation.

Asia Pacific: Surge in hospitalization rates, government initiatives to expand surgical care access, and growing awareness of multimodal pain therapy.

Latin America: Rising private healthcare investments and partnerships with global pharma firms to address unmet needs.

Middle East & Africa: Infrastructure modernization in Gulf states and policy reforms to enhance postoperative care standards.

The regional forecast underscores Asia Pacific as a transformative growth engine, with demographic tailwinds and infrastructure upgrades unlocking new opportunities. Meanwhile, North America and Europe remain pivotal for shaping premium therapeutics and regulatory benchmarks, ensuring a balanced global postoperative pain control drug market trajectory.

Competitive Landscape

The postoperative pain control drug market remains moderately consolidated, with a mix of global pharmaceutical firms and regional players competing on pricing, product innovation, and regulatory approvals. Key players in the postoperative pain control drug competitive landscape leverage differentiated portfolios, including extended-release formulations and multimodal therapies, to address unmet clinical needs. While large firms dominate high-margin markets via patented drugs, local manufacturers gain traction in price-sensitive regions through generic equivalents and localized distribution networks. Regulatory milestones, such as FDA approvals for novel analgesics, remain critical differentiators, alongside strategic partnerships with hospital systems and specialty pharmacies to secure formulary access.

Strategies across the sector emphasize R&D investment for next-generation pain solutions and geographic expansion into emerging markets. Companies navigate margin pressures from biosimilar competition and stringent compliance costs, particularly in regions with value-based pricing frameworks. Differentiation hinges on technology platforms (e.g., abuse-deterrent formulations), service models (e.g., patient adherence programs), and supply chain resilience. Collaborations with contract development organizations (CDOs) are growing to reduce time-to-market for complex drug delivery systems, though supply chain volatility remains a persistent risk.

Mallinckrodt Pharmaceuticals: Innovation pipeline for multimodal analgesic combinations

Pfizer: Partnerships to expand hospital-centric distribution networks

Novartis: Expansion of extended-release opioid alternatives in Asia-Pacific

Teva Pharmaceutical Industries: Cost-advantaged generic portfolio penetration

Camurus: Abuse-deterrent formulation technology commercialization

Pacira BioSciences: Focus on non-opioid local anesthetic product launches

Key postoperative pain control drug Companies9 items

Mallinckrodt Pharmaceuticals

Pfizer

Novartis

Eli Lilly and Company

Teva Pharmaceutical Industries

Camurus

Bayer

Pacira BioSciences

Trevena

Market Ecosystem

The postoperative pain control drug ecosystem spans upstream development and manufacturing, midstream formulation and distribution, and downstream clinical application. Value is created through research, production, and delivery of analgesic therapies, while capture occurs via sales, regulatory compliance, and clinical adoption.

Raw Material Suppliers – provide APIs and excipients for drug formulation

Active Pharmaceutical Ingredient (API) Manufacturers – synthesize key analgesic compounds

Contract Development and Manufacturing Organizations (CDMOs) – produce finished drug products

Pharmaceutical Companies – commercialize branded pain control medications

Distributors/Pharmacy Chains – manage logistics and retail distribution networks

Healthcare Providers/Administrators – prescribe and administer pain management therapies

Regulatory Bodies – establish approval pathways and safety standards

Control points in the postoperative pain control drug value chain analysis reside with regulators determining approval timelines and payers influencing reimbursement. Dependency risks include API supply chain disruptions and patent litigation delays. Switching costs for providers are low due to generic alternatives, but partnerships with CDMOs remain critical for maintaining production capacity.

Recent Industry Insights

The postoperative pain control drug industry trends reveal a dynamic landscape driven by innovation and regulatory shifts. Over the past 18 months, strategic partnerships between pharmaceutical giants and biotech firms have accelerated pipeline development, notably Merck & Co. collaborating with a specialist biotech to advance novel non-opioid analgesics. Mergers & acquisitions have intensified, with Pfizer acquiring a mid-sized firm to bolster its portfolio in long-acting pain therapies. Product/technology launches highlight a surge in extended-release formulations, such as Allergan’s approval of a 72-hour injectable drug, reducing hospital readmissions. Regulatory bodies, including the FDA, have tightened opioid-related guidelines, pushing manufacturers to prioritize non-opioid alternatives, sparking a 25% rise in R&D investments for peripheral nerve modulators. Consumer trends now favor multimodal therapies, blending pharmacological and digital solutions, while enterprise trends show a shift toward AI-driven pain management platforms. Funding rounds have surged, with startups securing $150M+ in Series B rounds to develop gene-based pain treatments, signaling long-term confidence in the sector’s innovation curve.

Analyst Overview

The postoperative pain control drug market outlook remains robust, driven by rising surgical volumes, aging demographics, and growing adoption of minimally invasive procedures. Market attractiveness is bolstered by unmet needs in chronic pain management and favorable reimbursement policies in developed regions. However, competitive intensity is escalating, with key players leveraging portfolios of opioids, NSAIDs, and emerging non-opioid analgesics to capture market share. Strategic partnerships and geographic expansion are critical differentiators in this fragmented landscape.

Key Insights4 items

Long-term outlook is optimistic, with demand projected to grow at a CAGR exceeding 6% through 2030, fueled by innovation in drug delivery systems and personalized pain therapies.

Innovation landscape highlights advancements in extended-release formulations and biosimilars, though regulatory hurdles may delay pipeline candidates.

Demand–supply balance currently favors suppliers, but potential shortages of generic opioids could arise due to manufacturing constraints or policy shifts.

Key risk factors include stringent FDA oversight, litigation risks tied to opioid products, and pricing pressures from generic competition.

12 items

1. Executive Summary

2. postoperative pain control drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global postoperative pain control drug Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global postoperative pain control drug Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global postoperative pain control drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global postoperative pain control drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global postoperative pain control drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global postoperative pain control drug Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global postoperative pain control drug Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global postoperative pain control drug Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global postoperative pain control drug Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global postoperative pain control drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global postoperative pain control drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global postoperative pain control drug Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global postoperative pain control drug Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global postoperative pain control drug Market Competition by Key Manufacturers

9.1. Global postoperative pain control drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global postoperative pain control drug: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Mallinckrodt Pharmaceuticals

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Pfizer

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Novartis

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Eli Lilly and Company

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Teva Pharmaceutical Industries

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Camurus

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Bayer

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Pacira BioSciences

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Trevena

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global postoperative pain control drug Market

Figure 4: Global postoperative pain control drug Market: Drivers

Figure 5: Global postoperative pain control drug Market: Challenges

Figure 6: Global postoperative pain control drug Market: Trends

Figure 7: Global postoperative pain control drug Market: Opportunity

Figure 8: Global postoperative pain control drug Market: Restraint

Figure 9: Global postoperative pain control drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global postoperative pain control drug Market Value (USD Million) By Region

Figure 19: Global postoperative pain control drug Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global postoperative pain control drug Market Value (USD Million) By Region

Figure 27: Global postoperative pain control drug Market Share (%) By: Regions (2032)

Figure 28: Global postoperative pain control drug Market Volume (K) By Region

Figure 29: Global postoperative pain control drug Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global postoperative pain control drug Market Value (USD Million) By Region

Figure 37: Global postoperative pain control drug Market Share (%) By: Regions (2032)

Figure 38: Global postoperative pain control drug Market Volume (K) By Region

Figure 39: Global postoperative pain control drug Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global postoperative pain control drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global postoperative pain control drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global postoperative pain control drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global postoperative pain control drug Market Value (USD Million) By Region

Table 14: Global postoperative pain control drug Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global postoperative pain control drug Market Volume (K) By Region

Table 31: Global postoperative pain control drug Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global postoperative pain control drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global postoperative pain control drug Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global postoperative pain control drug Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Mallinckrodt Pharmaceuticals Basic Information And Sales Area

Table 52: Mallinckrodt Pharmaceuticals. Products Portfolio

Table 53: Pfizer Basic Information And Sales Area

Table 54: Pfizer. Products Portfolio

Table 55: Novartis Basic Information And Sales Area

Table 56: Novartis. Products Portfolio

Table 57: Eli Lilly and Company Basic Information And Sales Area

Table 58: Eli Lilly and Company. Products Portfolio

Table 59: Teva Pharmaceutical Industries Basic Information And Sales Area

Table 60: Teva Pharmaceutical Industries. Products Portfolio

Table 61: Camurus Basic Information And Sales Area

Table 62: Camurus. Products Portfolio

Table 63: Bayer Basic Information And Sales Area

Table 64: Bayer. Products Portfolio

Table 65: Pacira BioSciences Basic Information And Sales Area

Table 66: Pacira BioSciences. Products Portfolio

Table 67: Trevena Basic Information And Sales Area

Table 68: Trevena. Products Portfolio

Table 69: Global Market Value (USD Million) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Value (USD Million) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Market Volume (K) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global postoperative pain control drug Market Value (USD Million) By Region

Table 78: Global postoperative pain control drug Market Share (%) By Region (2025-2032)

Table 79: North America Market Value (USD Million) (2025-2032) By Country

Table 80: North America Market Value (USD Million) (2025-2032) By Application

Table 81: North America Market Value (USD Million) (2025-2032) By Types

Table 82: Europe Market Value (USD Million) (2025-2032) By Country

Table 83: Europe Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Types

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 88: South America Market Value (USD Million) (2025-2032) By Country

Table 89: South America Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Types

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 94: Global postoperative pain control drug Market Volume (K) By Region

Table 95: Global postoperative pain control drug Market Share (%) By Region (2025-2032)

Table 96: North America Market Volume (K) (2025-2032) By Country

Table 97: North America Market Volume (K) (2025-2032) By Application

Table 98: North America Market Volume (K) (2025-2032) By Types

Table 99: Europe Market Volume (K) (2025-2032) By Country

Table 100: Europe Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Types

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 103: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 105: South America Market Volume (K) (2025-2032) By Country

Table 106: South America Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Types

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 109: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

postoperative pain control drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 billion
Revenue forecast in 2033	22.32 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mallinckrodt Pharmaceuticals; Pfizer; Novartis; Eli Lilly and Company; Teva Pharmaceutical Industries; Camurus; Bayer; Pacira BioSciences; Trevena
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

postoperative pain control drug Segmentation Breakdown12 items

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Types

Opioids

NSAIDs

Local Anesthetics

Tricyclic Antidepressants

Antiepileptic Drugs

Others

Regional Insights

Loading chart…

Regional Drivers & Dynamics5 items

North America: Aging demographics, high prevalence of chronic conditions, and payer reimbursement policies favoring advanced analgesics.

Europe: Stringent postoperative pain management guidelines, strong geriatric care infrastructure, and cross-border collaborations for drug innovation.

Asia Pacific: Surge in hospitalization rates, government initiatives to expand surgical care access, and growing awareness of multimodal pain therapy.

Latin America: Rising private healthcare investments and partnerships with global pharma firms to address unmet needs.

Middle East & Africa: Infrastructure modernization in Gulf states and policy reforms to enhance postoperative care standards.

Competitive Landscape

Mallinckrodt Pharmaceuticals: Innovation pipeline for multimodal analgesic combinations

Pfizer: Partnerships to expand hospital-centric distribution networks

Novartis: Expansion of extended-release opioid alternatives in Asia-Pacific

Teva Pharmaceutical Industries: Cost-advantaged generic portfolio penetration

Camurus: Abuse-deterrent formulation technology commercialization

Pacira BioSciences: Focus on non-opioid local anesthetic product launches

Key postoperative pain control drug Companies9 items

Mallinckrodt Pharmaceuticals

Pfizer

Novartis

Eli Lilly and Company

Teva Pharmaceutical Industries

Camurus

Bayer

Pacira BioSciences

Trevena

Market Ecosystem

Raw Material Suppliers – provide APIs and excipients for drug formulation

Active Pharmaceutical Ingredient (API) Manufacturers – synthesize key analgesic compounds

Contract Development and Manufacturing Organizations (CDMOs) – produce finished drug products

Pharmaceutical Companies – commercialize branded pain control medications

Distributors/Pharmacy Chains – manage logistics and retail distribution networks

Healthcare Providers/Administrators – prescribe and administer pain management therapies

Regulatory Bodies – establish approval pathways and safety standards

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-term outlook is optimistic, with demand projected to grow at a CAGR exceeding 6% through 2030, fueled by innovation in drug delivery systems and personalized pain therapies.

Innovation landscape highlights advancements in extended-release formulations and biosimilars, though regulatory hurdles may delay pipeline candidates.

Demand–supply balance currently favors suppliers, but potential shortages of generic opioids could arise due to manufacturing constraints or policy shifts.

Key risk factors include stringent FDA oversight, litigation risks tied to opioid products, and pricing pressures from generic competition.

Table of Contents